EFG International AG purchased a new stake in shares of Glaukos Corporation (NYSE:GKOS – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 51,290 shares of the medical instruments supplier’s stock, valued at approximately $7,161,000.
Several other hedge funds have also recently bought and sold shares of the business. Allworth Financial LP purchased a new position in Glaukos during the 2nd quarter valued at about $28,000. Los Angeles Capital Management LLC purchased a new stake in shares of Glaukos in the fourth quarter worth approximately $28,000. Larson Financial Group LLC boosted its holdings in shares of Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares during the period. Parallel Advisors LLC grew its position in Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its position in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 215 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.
Glaukos Price Performance
Shares of GKOS opened at $181.48 on Wednesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The firm has a market cap of $10.70 billion, a PE ratio of -55.84 and a beta of 0.78. The firm’s 50 day moving average price is $159.57 and its 200 day moving average price is $132.67. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $191.62.
Insider Buying and Selling at Glaukos
In related news, Director Gilbert H. Kliman sold 2,500 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the sale, the director directly owned 37,406 shares in the company, valued at approximately $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Leana Wen sold 525 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $167.63, for a total transaction of $88,005.75. Following the transaction, the director directly owned 21,092 shares in the company, valued at $3,535,651.96. The trade was a 2.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 113,025 shares of company stock valued at $19,600,006. Company insiders own 5.90% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Needham & Company LLC upped their price target on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. William Blair reiterated an “outperform” rating on shares of Glaukos in a report on Tuesday, May 26th. BTIG Research increased their price objective on Glaukos from $193.00 to $202.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Finally, JPMorgan Chase & Co. lifted their price objective on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $178.08.
Check Out Our Latest Research Report on Glaukos
About Glaukos
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Articles
- Five stocks we like better than Glaukos
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
